MYH14 and hydrops fetalis: Omecamtiv mecarbil, a cardiac-specific myosin activator, demonstrated a modest reduction in heart failure events and cardiovascular deaths in individuals with NYHA class III/IV HF in the recent GALACTIC-HF trial [47].